GERN
NASDAQ · Biotechnology
Geron Corp
$1.30
-0.02 (-1.52%)
Open$1.32
Previous Close$1.32
Day High$1.33
Day Low$1.29
52W High$2.01
52W Low$1.04
Volume—
Avg Volume11.07M
Market Cap835.22M
P/E Ratio—
EPS$-0.10
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,362.3% upside
Current
$1.30
$1.30
Target
$19.01
$19.01
$12.94
$19.01 avg
$24.33
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 168.14M | 153.95M | 141.15M |
| Net Income | -76,388,687 | -36,660,557 | -32,364,939 |
| Profit Margin | -45.4% | -23.8% | -22.9% |
| EBITDA | -62,305,857 | -44,322,691 | -40,350,825 |
| Free Cash Flow | — | -25,979,960 | -28,291,864 |
| Rev Growth | +574.2% | +15.1% | +6.9% |
| Debt/Equity | 1.10 | 0.42 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |